301096.SHE Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
- Market cap
- CNY 4.70B
- P/E
- -
- P/B
- 1.94x
- ROE
- -4.5%
- Dividend yield
- 0.44%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301096.SHE undervalued?
Graham numberThe Graham number of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. fundamental analysis
No fundamental analysis for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. yet.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical tria…
Full company profileHangzhou Bio-Sincerity Pharma-Tech Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 156M | 207M | 374M | 607M | 1.02B | 802M | 678M | 600M |
| Gross Profit | 97.3M | 136M | 252M | 409M | 667M | 417M | 268M | 247M |
| Operating Income | 50.7M | 65.8M | 125M | 161M | 298M | 16.4M | -25.7M | -77.0M |
| EBITDA | 65.6M | 85.2M | 158M | 257M | 393M | 127M | 87.5M | -90.0M |
| Net Income | 44.4M | 57.4M | 111M | 194M | 272M | -52.7M | -90.4M | -109M |
| EPS | 0.55 | 0.71 | 1.03 | 1.80 | 2.50 | -0.48 | -0.83 | -1.00 |
| Balance Sheet | ||||||||
| Total Assets | 379M | 659M | 2.92B | 2.93B | 3.67B | 3.72B | 3.69B | 3.68B |
| Total Liabilities | 99.9M | 319M | 607M | 447M | 985M | 1.14B | 1.20B | 1.26B |
| Shareholders' Equity | 278M | 340M | 2.32B | 2.48B | 2.68B | 2.58B | 2.49B | 2.43B |
| Cash & Short-term Investments | 189M | 134M | 2.01B | 1.24B | 882M | 429M | 293M | 334M |
| Cash Flow | ||||||||
| Operating Cash Flow | 71.5M | 54.4M | 145M | 259M | 90.5M | -196M | -155M | - |
| Capital Expenditure | 107M | 255M | 248M | 592M | 689M | 395M | 97.9M | 96.1M |
| Free Cash Flow | -35.5M | -201M | -103M | -332M | -598M | -591M | -253M | -114M |
| Ratios | ||||||||
| ROE | 15.9% | 16.9% | 4.8% | 7.8% | 10.1% | -2.0% | -3.6% | -4.5% |
| ROA | 11.7% | 8.7% | 3.8% | 6.6% | 7.4% | -1.4% | -2.5% | -3.0% |
| Net Profit Margin | 28.4% | 27.7% | 29.7% | 32.0% | 26.7% | -6.6% | -13.3% | -18.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. dividends
- Dividend yield
- 0.44%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 3, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.5M | 0.19 | - |
| 2024 | CNY 48.8M | 0.45 | - |
| 2023 | CNY 92.8M | 0.85 | 34.1% |
| 2022 | CNY 66.6M | 0.62 | 34.3% |
| 2021 | CNY 10.1M | 0.09 | 9.1% |
| 2020 | CNY 8.73M | 0.11 | 15.2% |
| 2019 | CNY 13.9M | 0.17 | 31.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
- Insiders 40.65%
- Institutions 8.39%
- Public & others 50.96%
- Shares outstanding 109M
- Free float 84.4M
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. company profile
- Company name
- Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
- Ticker
- 301096.SHE
- ISIN
- CNE1000056N5
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,412
- Fiscal year end
- December
- Address
- No. 159, Oasis Road, Hangzhou, China, 310000
- Phone
- 86 571 8792 3909
- Website
- hzbio-s.com
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business covers the principal links of drug discovery, pharmaceutical research, clinical trials, customized research and development and production, and registration applications. Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. was incorporated in 2011 and is headquartered in Hangzhou, China.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. management
5- Ms. Jinfang LouChairwoman of the Board & GM · born 1968
- Mr. Shufeng ChenFinancial Officer, Board Secretary & Director · born 1970
- Mr. Fei JiaDeputy GM & Director · born 1979
- Mr. An ChenDeputy General Manager · born 1974
- Ms. Miao LeiDeputy General Manager · born 1983